Aegle Therapeutics’ Post

The on-demand recording of the webinar 'Transforming RNA-Targeted Drug Discovery With MAGNA™ ', given by Gordon Hamilton last week is now available. As a quick recap, targeting RNA offers an opportunity to explore a new universe of therapeutics, but many small molecule drug candidates suffer from poor target selection and non-specific binding. MAGNA™ provides powerful insights to support target validation, hit-to-lead selection and lead optimization, accelerating RNA-targeted drug discovery. In this webinar, Gordon Hamilton, President & CEO, talks about how MAGNA™, an exciting new technology from Depixus based on magnetic force spectroscopy, can be used to: - Measure the dynamics of drug binding to RNA structures - Enable improved hit-to-lead selection through scalable, real time analysis - Study different small molecule-RNA target interactions, using recent data You can view the recording of this webinar here: https://lnkd.in/e7wg49YE #ELRIG2023 #DrugDiscovery #Biotech #rnatherapeutics

As you adventure into #Exosomes / #ExtracellularVesicles (EVs), manufacturers can gain insight into how critically important scalability is for future clinical products made from EVs, how the quality of peer-reviewed EV / exosome science can improve, and how VivaZome Therapeutics are leading the way into a new therapeutic ecosystem.

Studying protein structure, dynamics, and interactions is pivotal for understanding disease mechanisms and to advance drug discovery and development. Scientists at the Tatyana Polenova's Laboratory, University of Delaware, USA, are using #NMR spectroscopy to study large protein assemblies, advancing the understanding of disease mechanisms for the development of new therapeutics. Learn more: https://lnkd.in/dM95fsax #MakeMRmoreRelevant #Spectroscopy #UniversityofDelaware

RNA-targeted drug discovery and development remains a challenge for biotech and pharma. So what’s holding the field back? RNA is a largely unexplored drug target offering a promising approach to treat various diseases. However, current methods fall short in accurately measuring the dynamic interactions between small molecules and their target RNAs, and provide little to no information on the kinetics of binding between ligand and target. These limitations can be broadly categorized into three different categories: 📸 Static: Some technologies, such as X-ray crystallography, provide only snapshots of molecular interactions, with no information about what happened before or after that snapshot. 🧩 Indirect: Other approaches may observe molecular interactions more dynamically but produce inferred data from surrogate readouts. Examples include melt curves or fluorescent signals. 🧐 Unrepresentative: Many assays are bulk in nature, averaging data from thousands of simultaneous interactions. But this approach misses the important detail of what is happening at the level of individual interactions and doesn’t truly represent what is going on in biology. By contrast, our new revolutionary technology MAGNA™ is: 🎥 Dynamic: MAGNA can probe the dynamics of biomolecular interactions, and measure, in real-time, kinetic data coming from single or multi-ligand binding events. 🧬 Direct: MAGNA can directly monitor and measure binding forces and kinetics - without surrogate measurements. 🌎 Representative: MAGNA can analyze up to 200,000 molecules in parallel - and is able to generate data from individual biomolecular interactions, revealing all the action not just the averages. MAGNA provides real-time and comprehensive measurements of individual molecular interactions at scale. By directly measuring how small molecules destabilize or stabilize target RNAs and providing vital information about binding kinetics, MAGNA empowers you to pick the right targets, fail inappropriate candidates quickly, and ensure fast hit to lead and lead optimization. In our recent webinar, our CEO Gordon Hamilton delves into detail on how MAGNA works, and covers real-life case studies showing how this unique technology can be used to accelerate RNA-targeted drug discovery. Check it out here: https://lnkd.in/de4vejj4 #RNATherapeutics #DrugDiscovery #Biotech #interactomics #Depixus

One of myTRIAList's goals is to make it easier for people living with cancer and their care providers to understand and find the right clinical trial that is accessible to them geographically. Explore all that CancerCare's myTRIAList trial finder has to offer here: https://buff.ly/45gGIez #clinicaltrials #pharma #biotech #cancerresearch #science

Researchers, how would you propose to progress drug delivery systems for the posterior inner eye segment? Your solutions should ensure sustained release over at least three months for diverse therapeutics ranging from low molecular weight compounds to complex molecules. Learn more on our open science platform #opnMe: https://lnkd.in/gEDjfkdd

#News; #Interactomics pioneer Depixus, based in Paris, has entered a collaboration with Daiichi Sankyo, Inc. to use their novel MAGNA technology to accelerate the Japanese healthcare leader’s #RNA-targeted #drugdiscovery programme. Based on magnetic force spectroscopy, MAGNA is a unique technology that enables high-throughput analysis of dynamic biomolecular interactions in real time with single-molecule resolution. In the case of RNA, these insights reveal how small molecules and proteins bind to three-dimensional RNA structures and provide valuable information about binding kinetics and mode of action. The team at Daiichi Sankyo will use MAGNA to explore the interactions of lead molecules with a number of undisclosed RNA targets. This data will inform hit-to-lead selection and lead optimization, accelerating and de-risking the company’s RNA-targeted therapeutics pipeline as they move towards the clinic. Depixus is currently discussing collaborations with other global pharmaceutical and biotech partners to explore challenging novel targets and accelerate the next generation of life-changing therapeutics. The company is also aiming for the commercial launch of its MAGNA One instrument in 2024. Read more from BioSpectrum Asia 👇🏼 https://lnkd.in/eWYSgKE9 #RSKDepixus Nigel Skinner Gordon Hamilton Steve Allen Christine Blancher

Do you want to know how to combine active learning, synthesis on demand libraries, and fragment screening in early drug discovery? We've got you covered: Dr Pat Walters from Relay Therapeutics will be giving a talk at FBLD 2024. Register now via https://lnkd.in/gnvHkNyw and submit an abstract!

When Andrei Georgescu, Ph.D. and Dan Huh first shared the Vivodyne story with us we were struck by how their human-tissue platform would fundamentally reshape #drugdiscovery and #drugdevelopment. 90% of drugs that enter clinical trials ultimately fail. For a drug to reach human testing, the smartest scientists at each company have assessed the candidate and its associated data package and decided it is worth the expense and risk of testing in humans, and the FDA has given their stamp of approval. Up to this point, every computational model, cell-based assay, and animal model has suggested the candidate will have clinical efficacy with enough conviction to justify the exorbitant cost of a clinical trial. If we hope to have a shot at curing many of the world’s worst diseases, this 90% clinical failure rate must improve. We believe this is the most critical problem in drug discovery. Vivodyne is solving this problem head on. We are thrilled to support Andrei Georgescu, Ph.D., Susan Billings, Ph.D., Tony Bahinski and the rest of the Vivodyne alongside our partners Khosla Ventures, Kairos Ventures, MBX Capital and CS Ventures.